**Core Concept:** The blood-brain barrier (BBB) is a semi-selective barrier formed by the endothelial cells of cerebral blood vessels, which tightly regulates the transport of molecules and cells into the central nervous system (CNS). This is essential to maintain the homeostasis of the CNS.

**Why the Correct Answer is Right:** Drugs that do not cross the blood-brain barrier are mainly small, non-polar molecules with a molecular weight less than 400 Da and a log P (octanol-water partition coefficient) value less than 5. These drugs cannot passively diffuse through the BBB due to its tight junctions and lack of transporters for these specific molecules.

**Why Each Wrong Option is Incorrect:**

A. **Option A (Amphetamines):** Amphetamines are small, lipophilic molecules (log P > 5) which can cross the blood-brain barrier due to their high lipophilicity.

B. **Option B (Antidepressants):** Antidepressants are a diverse group of drugs, and not all of them do not cross the blood-brain barrier. Some antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), are small, lipophilic molecules with low molecular weights, making them capable of crossing the blood-brain barrier.

C. **Option C (Antipsychotics):** Not all antipsychotics do not cross the blood-brain barrier. First-generation antipsychotics (e.g., chlorpromazine) are typically large, polar molecules with high molecular weights and low log P values, which make them unable to cross the blood-brain barrier. However, second-generation antipsychotics (e.g., olanzapine) are small, lipophilic molecules with low molecular weights and moderate log P values, allowing them to cross the blood-brain barrier.

D. **Option D (Epinephrine):** Epinephrine is a small, lipophilic molecule with a low molecular weight and a moderate log P value, enabling it to cross the blood-brain barrier.

**Clinical Pearl:** A better understanding of the pharmacokinetics of drugs can help in selecting appropriate treatments for CNS disorders while avoiding potential adverse neuropsychiatric side effects caused by drugs crossing the blood-brain barrier unintentionally.